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Real world effect of biologics on life quality in psoriasis 
 
A well-planned and well-run clinical Registry is like a mine: just waiting for the 
surveyors to find another rich seam.  Iskander et al1 have struck more gold in the 
huge (and still growing) British Association of Dermatologists Biologic 
Interventions Register (BADBIR) dataset. Designed to monitor the realities of 
clinical practice, not the artificial topiary of randomised clinical trials (RCT) 
where tricky patients are pruned out, the study confirms that biologics produce 
marked improvement in quality of life (QoL).  And there is not much difference 
between the various biologics.  But if you are female, have co-morbidities, smoke 
and have considerable QoL impairment when starting a biologic, then you are 
less likely to reach a low level of QoL impairment. 
 
The improvement in QoL recorded in the real world of this registry is less than 
that suggested by RCTs.  Iskander et al1 suggest that life course impairment 
caused by psoriasis may explain why some patients continue to experience QoL 
impairment despite major clinical improvement.  BADBIR was set up before this 
concept, or the impact of disease on major life changing decisions2 was 
considered, but future psoriasis registry developers might consider tracking this 
long-term burden.  Whatever the explanation, this is another example of why 
guideline developers need to temper their reliance on “the highest ranking 
evidence” with the cold reality revealed by registries such as BADBIR. 
 
A systematic review of biologics in psoriasis3 concluded that ustekinumab was 
the most effective, followed by infliximab, adalimumab and etanercept, 
anticipating some aspects of the heirarchy revealed by the BADBIR study.  
Although not part of any planned Core Outcomes framework, the use of PASI and 
the Dermatology Life Quality Index (DLQI) in the majority of randomised 
controlled therapeutic trials in psoriasis4 has allowed comparison,5 illustrating 
the advantages of the objective of setting Core Outcome measures in psoriasis 
and other areas of dermatology.6,7  There are many reasons why routine 
measurement of QOL may be helpful clinically.8   This BADBIR study further 
emphasises the clinical importance of the concept of “QoL impairment”, which 
has lead to the proposal for a specific word to describe it.9 
 
So what are the messages for tomorrow’s clinic?  Your patient’s QoL will be 
improved by starting any of the three biologics investigated, but not by as much 
as was reported in previous RCTs.  Using ustekinumab or adalimumab gives you 
a better chance of reaching “no” impairment than using etanercept.  You can also 
now explain to patients that if they are male, have not smoked, have no co-
morbidities and have low QoL impairment they are more likely to reach a state of 
“no” QoL impairment, though presumably this will be a rather small sub-group. 
 
Could the authors have mined an even richer seam?  For example applying the 
“happy” drug survival concept,10 defined as a DLQI score < or = 5, might have 
revealed other clinically relevant differences between the biologics.  However 
the BADBIR miners should be congratulated on revealing the realities of biologic 
therapy and be encouraged to continue to dig deep. 
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